Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TLR2 | O60603 | 2/20 | 0.39 |
| ▸ | TLR1 | Q15399 | 2/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12164667 | 0.91 | BACE1 (0.44) | BACE1DGAT2USP30KMT2ATLR2 | |
| SCHEMBL5435274 | 0.86 | F10 (0.43) | BACE1DGAT2USP30KMT2ATLR2 | |
| SCHEMBL5435277 | 0.86 | F10 (0.43) | BACE1DGAT2USP30KMT2ATLR2 | |
| SCHEMBL21319696 | 0.82 | BACE1 (0.46) | BACE1USP30KMT2ATLR2TLR1 | |
| SCHEMBL25355246 | 0.81 | BACE1 (0.46) | BACE1USP30KMT2ANAMPTEPHX2 | |
| SCHEMBL14678450 | 0.80 | BACE1 (0.46) | BACE1USP30KMT2ATLR2TLR1 | |
| SCHEMBL29569298 | 0.80 | BACE1 (0.46) | BACE1USP30KMT2ATLR2TLR1 | |
| SCHEMBL742949 | 0.80 | BACE1 (0.46) | BACE1USP30KMT2ATLR2TLR1 | |
| SCHEMBL6344562 | 0.80 | BACE1 (0.46) | BACE1USP30KMT2ATLR2TLR1 | |
| SCHEMBL6349287 | 0.79 | BACE1 (0.45) | BACE1USP30KMT2ATLR2TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2315768-B1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2017-08-09 | — | — | EP | disclosed |
| US-8637491-B2 | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA S.A. (BE) | 2014-01-28 | — | — | US | disclosed |
| US-20110172191-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172191-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | MAP2K2, MAP2K1, MAP2K3 | BACE1 3495/4885DGAT2 4430/4885USP30 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.